Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3081-3088

  Ferrari, Anna C ^a   Stone, Nelson N ^b   Kurek, Ralf ^b   Mulligan, Elizabeth ^b   McGregor, Roy ^b   Stock, Richard ^b   Unger, Pamela ^b   Tunn, Ulf ^b   Kaisary, Amir ^b   Droller, Michael ^b   Hall, Simon ^b   Renneberg, Heiner ^b   Livak, Kenneth J ^b   Gallagher, Robert E ^b   Mandeli, John ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; GONADORELIN AGONIST; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33746017350     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6020     Document Type: Article

References (51)

1. Jemal A, Twari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150:110-114, 1993
3. Kattan M, Eastham J, Stapleton A, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
4. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
5. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomograms that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568-4571, 2003
6. D'Amico AV, Cote K, Lofredo M, et al: Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170:S42-S47, 2003
7. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004
8. Lee W, Hanks G, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-237, 1997
9. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
10. Ravery V: The significance of recurrent PSA after radical prostatectomy: Benign versus malignant sources. Sem Urol Oncol 17:127-129, 1999
11. Swindle PW, Kattan MW, Scardino PT: Markers and meaning of primary treatment failure. Urol Clin North Am 30:377-401, 2003
12. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
13. Roehl KA, Han M, Ramos CG, et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172:910-914, 2004
14. Deguchi T, Doi T, Ehara H, et al: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 53:5350-5354, 1993
15. Edelstein RA, Krane RJ, Babayan RK, et al: A rapid and simple method for the detection of prostate-specific antigen mRNA in archival tissue specimens using a reverse transcription-polymerase chain reaction assay. Urology 45:597-603, 1995
16. Ferrari A, Stone N, Eyler J, et al: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 89:1498-1504, 1997
17. Kurek R, Nunez G, Tselis N, et al: Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 10:5808-5814, 2004
18. Shariat SF, Kattan MW, Erdamar S, et al: Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific RT-PCR assay for human glandular kallikrein. J Clin Oncol 21:1223-1231, 2003
19. Katz AE, deVries GM, Begg MD, et al: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75:1642-1648, 1995
20. Israeli R, Miller WH, Su SL, et al: Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153:573-577, 1994
21. Thomas J, Gupta M, Grasso Y, et al: Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 20:3213-3218, 2002
22. Ellis WJ, Pfitzenmaier J, Colli J, et al: Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 61:277-281, 2003
23. Beahrs O, Henson D, Hutter R: American Joint Committee on Cancer: Manual for Staging Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
24. Stone N, Stock R, Unger P: Laparoscopic pelvic lymph node dissection: Comparison of extended and modified techniques. J Urol 158:1891-1894, 1997
25. Golimbu M, Morales P, Al-Askari S, et al: Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617-621, 1979
26. Stone NN, Stock RG: Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation. Techniq Urol 1:72-80, 1995
27. Heid CA, Stevens J, Livak KJ, et al: Real-time quantitative PCR. Genome Res 6:986-994, 1996
28. Lange P, Ercole C, Lightner D, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873-879, 1989
29. Pound C, Partin A, Epstein J, et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 24:395-406, 1997
30. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
31. Shipley W, Thames H, Sandler H, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281:1598-1603, 1999
32. Han M, Partin A, Pound C, et al: Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
33. Hull GW, Rabbani F, Abbas F, et al: Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167:528-534, 2002
34. Lau W, Bergstralh E, Blute M, et al: Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. J Urol 167:117, 2002
35. Grossfeld G, Latini D, Lubeck D, et al: Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157-163, 2003
36. Kattan MW: Evaluating a new marker's predictive contribution. Clin Cancer Res 10:822-824, 2004
37. Gomella LG, White JL, McCue PA, et al: Screening for occult nodal metastasis in localized carcinoma of the prostate. J Urol 149:776-778, 1993
38. Potter SR, Mangold LA, Shue MJ, et al: Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 89:2577-2586, 2000
39. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
40. Freedland SJ, Isaacs WB, Platz EA, et al: Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study. J Clin Oncol 23:7546-7554, 2005
41. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
42. Zagars G, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997
43. Ward J, Blute M, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:2260-2264, 2003
44. Okotie O, Aaronson W, Wiedler J, et al: Predictors of metastatic disease in men with biochemical failure after radical prostatectomy. J Urol 171:2260-2264, 2004
45. Kelloff GJ, Coffey DS, Chabner BA, et al: Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 10:3927-3933, 2004
46. Luzzi K, MacDonald I, Schmidt E, et al: Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation. Am J Path 153:865-873, 1998
47. Ghiso J, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89-103, 1999
48. Lerner S, Blute M, Bergstralh E, et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156:137-143, 1996
49. Meng MV, Elkin EP, Latini DM, et al: Treatment of patients with high risk localized prostate cancer: Results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 173:1557-1561, 2005
50. Amling C, Blute M, Bergstralh E, et al: Long-term hazard of progression after radicial prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years J Urol 167:528-534, 2000
51. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005